Related references
Note: Only part of the references are listed.Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial
Elena Guerini-Rocco et al.
CLINICAL CANCER RESEARCH (2021)
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
Erica L. Mayer et al.
LANCET ONCOLOGY (2021)
Liquid biopsy enters the clinic - implementation issues and future challenges
Michail Ignatiadis et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial
S. Dent et al.
ANNALS OF ONCOLOGY (2021)
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2enegative advanced breast cancer: final overall survival results from SOLAR-1
F. Andre et al.
ANNALS OF ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer
Neelima Vidula et al.
CLINICAL CANCER RESEARCH (2021)
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial
Sibylle Loibl et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Genomic profile of advanced breast cancer in circulating tumour DNA
Belinda Kingston et al.
NATURE COMMUNICATIONS (2021)
Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy
E. Ortolan et al.
ESMO OPEN (2021)
Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden
Peter Peneder et al.
NATURE COMMUNICATIONS (2021)
Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients
Lauren Darrigues et al.
BREAST CANCER RESEARCH (2021)
Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study
Rina Hui et al.
CLINICAL CANCER RESEARCH (2020)
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer
F. Mosele et al.
ANNALS OF ONCOLOGY (2020)
Circulating breast-derived DNA allows universal detection and monitoring of localized breast cancer
J. Moss et al.
ANNALS OF ONCOLOGY (2020)
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
Wassim Abida et al.
CLINICAL CANCER RESEARCH (2020)
Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis.
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Prognostic impact of ESR1 mutations in ER+ HER2- MBC patients prior treated with first line AI and palbociclib: An exploratory analysis of the PADA-1 trial.
Francois Clement Bidard et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention
Anne Marie Lennon et al.
SCIENCE (2020)
Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma
Lennart Raman et al.
GENOME MEDICINE (2020)
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
M. C. Liu et al.
ANNALS OF ONCOLOGY (2020)
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial
Douglas Yee et al.
JAMA ONCOLOGY (2020)
Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial
Milan Radovich et al.
JAMA ONCOLOGY (2020)
Landscape of circulating tumour DNA in metastatic breast cancer
Andrew A. Davis et al.
EBIOMEDICINE (2020)
Shallow Whole-Genome Sequencing from Plasma Identifies FGFR1 Amplified Breast Cancers and Predicts Overall Survival
Chantal Bourrier et al.
CANCERS (2020)
Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) plus fulvestrant (FUL) for hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2e) advanced breast cancer (ABC)
F. Andre et al.
ANNALS OF ONCOLOGY (2020)
Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis
Min Huang et al.
CANCER RESEARCH (2020)
ctDNA monitoring using patient-specific sequencing and integration of variant reads
Jonathan C. M. Wan et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Non-invasive early detection of cancer four years before conventional diagnosis using a blood test
Xingdong Chen et al.
NATURE COMMUNICATIONS (2020)
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
Wassim Abida et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Association of a Diagnosis of Ductal Carcinoma In Situ With Death From Breast Cancer
Vasily Giannakeas et al.
JAMA NETWORK OPEN (2020)
Liquid biopsy versus tumor biopsy for clinical-trial recruitment
Ryan B. Corcoran
NATURE MEDICINE (2020)
Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer A Systematic Review and Meta-analysis
Carolyn Cullinane et al.
JAMA NETWORK OPEN (2020)
Mechanisms Underlying Recurrent Genomic Amplification in Human Cancers
Hisashi Tanaka et al.
TRENDS IN CANCER (2020)
Performance evaluation of commercial library construction kits for PCR-based targeted sequencing using a unique molecular identifier
Jongsuk Chung et al.
BMC GENOMICS (2019)
Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Francoise Rothe et al.
CLINICAL CANCER RESEARCH (2019)
Guidelines for the Preanalytical Conditions for Analyzing Circulating Cell-Free DNA
Romain Meddeb et al.
CLINICAL CHEMISTRY (2019)
Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence
Raoul Charles Coombes et al.
CLINICAL CANCER RESEARCH (2019)
Genome-wide cell-free DNA fragmentation in patients with cancer
Stephen Cristiano et al.
NATURE (2019)
Genomic characterization of metastatic breast cancers
Francois Bertucci et al.
NATURE (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast Cancer
Xianyu Zhang et al.
CLINICAL CANCER RESEARCH (2019)
PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study
Eleni Tzanikou et al.
MOLECULAR ONCOLOGY (2019)
Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer
Isaac Garcia-Murillas et al.
JAMA ONCOLOGY (2019)
Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis
Ben O'Leary et al.
CLINICAL CHEMISTRY (2019)
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
Aparna R. Parikh et al.
NATURE MEDICINE (2019)
Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA
Shu Yi Shen et al.
NATURE PROTOCOLS (2019)
How liquid biopsies can change clinical practice in oncology
G. Siravegna et al.
ANNALS OF ONCOLOGY (2019)
Toward the Early Detection of Cancer by Decoding the Epigenetic and Environmental Fingerprints of Cell-Free DNA
Ymke van der Pol et al.
CANCER CELL (2019)
Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort
Xiaoji Chen et al.
CLINICAL CANCER RESEARCH (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cancer overdiagnosis: a biological challenge and clinical dilemma
Sudhir Srivastava et al.
NATURE REVIEWS CANCER (2019)
Proteins and antibodies in serum, plasma, and whole blood-size characterization using asymmetrical flow field-flow fractionation (AF4)
Mats Leeman et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2018)
Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification
L. Liu et al.
ANNALS OF ONCOLOGY (2018)
Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer
N. Guibert et al.
ANNALS OF ONCOLOGY (2018)
False-Positive Plasma Genotyping Due to Clonal Hematopoiesis
Yuebi Hu et al.
CLINICAL CANCER RESEARCH (2018)
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
Elisa Gobbini et al.
EUROPEAN JOURNAL OF CANCER (2018)
Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer
Daniel G. Stover et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer
Annette R. Kodahl et al.
MOLECULAR ONCOLOGY (2018)
Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations
Jesse J. Salk et al.
NATURE REVIEWS GENETICS (2018)
Cost-effectiveness of an autoantibody test (EarlyCDT-Lung) as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules
John Edelsberg et al.
PLOS ONE (2018)
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Joshua D. Cohen et al.
SCIENCE (2018)
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer
Ben O'Leary et al.
NATURE COMMUNICATIONS (2018)
Evaluation of droplet digital PCR and next generation sequencing for characterizing DNA reference material for KRAS mutation detection
Lianhua Dong et al.
SCIENTIFIC REPORTS (2018)
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Pedram Razavi et al.
CANCER CELL (2018)
Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients
Bente Risberg et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2018)
A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer
Tanya T. Kwan et al.
CANCER DISCOVERY (2018)
Centrifugation affects the purity of liquid biopsy-based tumor biomarkers
Linda G. Rikkert et al.
CYTOMETRY PART A (2018)
Sensitive tumour detection and classification using plasma cell-free DNA methylomes
Shu Yi Shen et al.
NATURE (2018)
Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer
Marcus D. Goncalves et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Enhanced detection of circulating tumor DNA by fragment size analysis
Florent Mouliere et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease
Joshua Moss et al.
NATURE COMMUNICATIONS (2018)
Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review
Jennifer L. Caswell-Jin et al.
JNCI CANCER SPECTRUM (2018)
Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma
Tatyana Vagner et al.
JOURNAL OF EXTRACELLULAR VESICLES (2018)
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
W. Shi et al.
ANNALS OF ONCOLOGY (2017)
The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA
Sonya Parpart-Li et al.
CLINICAL CANCER RESEARCH (2017)
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype
W. Fraser Symmans et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Jose Baselga et al.
LANCET ONCOLOGY (2017)
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher et al.
LANCET ONCOLOGY (2017)
Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditions
Lisanne F. van Dessel et al.
MOLECULAR ONCOLOGY (2017)
Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA
Shicheng Guo et al.
NATURE GENETICS (2017)
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Hongchao Pan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
N. Masuda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Direct detection of early-stage cancers using circulating tumor DNA
Jillian Phallen et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
Viktor A. Adalsteinsson et al.
NATURE COMMUNICATIONS (2017)
Liquid biopsy in colon cancer: comparison of different circulating DNA extraction systems following absolute quantification of KRAS mutations using Intplex allele-specific PCR
Vera Kloten et al.
ONCOTARGET (2017)
Retrospective analysis of the role of CA 15-3 as a biomarker for breast cancer relapse.
Marwan Elahi Shaikh et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Shallow Whole Genome Sequencing on Circulating Cell-Free DNA Allows Reliable Noninvasive Copy-Number Profiling in Neuroblastoma Patients
Nadine Van Roy et al.
CLINICAL CANCER RESEARCH (2017)
Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
Cynthia X. Ma et al.
CLINICAL CANCER RESEARCH (2017)
Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
Yu-Hsiang Chen et al.
NPJ BREAST CANCER (2017)
Genomic Evolution of Breast Cancer Metastasis and Relapse
Lucy R. Yates et al.
CANCER CELL (2017)
Liquid biopsies come of age: towards implementation of circulating tumour DNA
Jonathan C. M. Wan et al.
NATURE REVIEWS CANCER (2017)
Patient -Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple -Negative Breast Cancer
Francesca Riva et al.
CLINICAL CHEMISTRY (2017)
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
Nicholas McGranahan et al.
CELL (2017)
ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients
David Chu et al.
CLINICAL CANCER RESEARCH (2016)
Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients
Peilu Wang et al.
CLINICAL CANCER RESEARCH (2016)
Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes
Qing Kang et al.
CLINICAL BIOCHEMISTRY (2016)
Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
Jeffrey C. Thompson et al.
CLINICAL CANCER RESEARCH (2016)
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer
Charlotte Fribbens et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival
Ann H. Partridge et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2016)
Integrated digital error suppression for improved detection of circulating tumor DNA
Aaron M. Newman et al.
NATURE BIOTECHNOLOGY (2016)
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness
H. Gilbert Welch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
P. E. Goss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The Long and Short of Circulating Cell-Free DNA and the Ins and Outs of Molecular Diagnostics
Peiyong Jiang et al.
TRENDS IN GENETICS (2016)
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
Jill M. Spoerke et al.
NATURE COMMUNICATIONS (2016)
Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor
Florian Clatot et al.
ONCOTARGET (2016)
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer A Secondary Analysis of the BOLERO-2 Clinical Trial
Sarat Chandarlapaty et al.
JAMA ONCOLOGY (2016)
Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer
Adrian G. Sacher et al.
JAMA ONCOLOGY (2016)
Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC)
James L. Sherwood et al.
PLOS ONE (2016)
Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer
Tara Sanft et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics
Myron G. Best et al.
CANCER CELL (2015)
PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer
Ian J. Majewski et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291
Kenneth S. Thress et al.
LUNG CANCER (2015)
Clinical management of breast cancer heterogeneity
Dimitrios Zardavas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments
Kun Sun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
Isaac Garcia-Murillas et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4(+) T cells in human melanoma
Carsten Linnemann et al.
NATURE MEDICINE (2015)
Liquid Biopsies: Genotyping Circulating Tumor DNA
Luis A. Diaz et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Addressing overdiagnosis and overtreatment in cancer: a prescription for change
Laura J. Esserman et al.
LANCET ONCOLOGY (2014)
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Aaron M. Newman et al.
NATURE MEDICINE (2014)
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
Alain R. Thierry et al.
NATURE MEDICINE (2014)
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Giulio Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Direct Quantification of Cell-Free, Circulating DNA from Unpurified Plasma
Sarah Breitbach et al.
PLOS ONE (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Breast Cancer Index Identifies Early-Stage Estrogen Receptor-Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence
Yi Zhang et al.
CLINICAL CANCER RESEARCH (2013)
Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
Christina Davies et al.
LANCET (2013)
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy et al.
NATURE GENETICS (2013)
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Dan R. Robinson et al.
NATURE GENETICS (2013)
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
Paul F. Robbins et al.
NATURE MEDICINE (2013)
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Sarah-Jane Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Detection of ultra-rare mutations by next-generation sequencing
Michael W. Schmitt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA
Tim Forshew et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
A Modified Extraction Method of Circulating Free DNA for Epidermal Growth Factor Receptor Mutation Analysis
Haihua Yuan et al.
YONSEI MEDICAL JOURNAL (2012)
Update on Mammography Trends Comparisons of Rates in 2000, 2005, and 2008
Nancy Breen et al.
CANCER (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Breast Carcinomas Arising at a Young Age: Unique Biology or a Surrogate for Aggressive Intrinsic Subtypes?
Carey K. Anders et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS
Irene L. Wapnir et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Molecular Stratification of Triple-Negative Breast Cancers
Charles M. Perou
ONCOLOGIST (2011)
Detection and quantification of rare mutations with massively parallel sequencing
Isaac Kinde et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S. Albain et al.
LANCET ONCOLOGY (2010)
Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer
Heidi Schwarzenbach et al.
CIRCULATING NUCLEIC ACIDS IN PLASMA AND SERUM V (2008)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Circulating mutant DNA to assess tumor dynamics
Frank Diehl et al.
NATURE MEDICINE (2008)
Circulating microRNAs as stable blood-based markers for cancer detection
Patrick S. Mitchell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer
Lyndsay Harris et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
[Anonymous]
JOURNAL OF ONCOLOGY PRACTICE (2007)
Ethnic and geographic differences in mammographic density and their association with breast cancer incidence
Gertraud Maskarinec et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Quantity versus quality: Optimal methods for cell-free DNA isolation from plasma of pregnant women
Carolina J. Jorgez et al.
GENETICS IN MEDICINE (2006)
Prediction of breast tumor progression by integrity of free circulating DNA in serum
Naoyuki Umetani et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Changes in concentration of DNA in serum and plasma during storage of blood samples
M Jung et al.
CLINICAL CHEMISTRY (2003)
Long-term effects of mammography screening:: updated overview of the Swedish randomised trials
L Nyström et al.
LANCET (2002)
Share Paper
